Figure 6.
SUREK outperforms ch14.18 in vivo. (A) Treatment and analysis scheme. A/J mice were injected with 5×105 NXS2 cells into a tail vein (intravenous) and received two intraperitoneal (i.p.) injections with 5 µg of SUREK (n=6) or TRBs012 (n=5) or ch14.18 (n=6) on days (d)+1 and +5 and a single injection of 1 µg of the respective antibody on d+9 after tumor cell inoculation. Control mice received three injections with PBS (n=5). (B) Exemplary images of liver specimen in animals treated with SUREK, ch14.18, TRBs012 or PBS. Scale bar equals 10 mm. (C) After 21 d, mice were sacrificed and liver metastases were macroscopically counted. Results are pooled from two independent experiments. Mann-Whitney test; *p<0.05; **p<0.01; n.s., not significant.